New perspectives in the treatment of patients with intermediate-2 and high-risk myelodysplastic syndrome
Currently, therapeutic tactics in patients with myelodysplastic syndrome is based on risk-adapted therapy followed by allogeneic hematopoietic stem cell transplantation, which remains the only radical method of treatment. for patients who cannot undergo transplantation, the problem of finding new me...
Saved in:
| Main Authors: | E. V. Morozova, N. Yu. Tsvetkov, M. V. Barabanshchikova, K. S. Yurovskaya, I. S. Moiseev |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2022-11-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/594 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of Pre‐Treatment Serum Ferritin on Response and Survival in Myelodysplastic Syndromes Treated With Azacytidine: A Multivariate Analysis
by: Gloria Moreno Carrasco, et al.
Published: (2025-08-01) -
Phenotypic and functional changes of NK cells in patients with myelodysplastic syndrome and acute myeloid leukemia treated with hypomethylating drugs
by: D. I. Zhigarev, et al.
Published: (2021-05-01) -
Myelodysplastic Syndrome in a Patient With Cronkhite‐Canada Syndrome
by: Kevin G. Shim, et al.
Published: (2025-08-01) -
Study of myelodysplastic features in patients with myelodysplastic syndromes by multicolor flow cytometry
by: O. Yu. Davydova, et al.
Published: (2019-01-01) -
Disseminated tuberculosis masquerading primary myelodysplastic syndrome
by: Syahrul Sazliyana Shaharir, et al.
Published: (2013-03-01)